Journal
NATURE REVIEWS NEUROSCIENCE
Volume 16, Issue 1, Pages 30-42Publisher
NATURE RESEARCH
DOI: 10.1038/nrn3876
Keywords
-
Categories
Funding
- Deutsche Forschungsgemeinschaft [FOR926, SFB645]
- US National Institutes of Health (NIH) [DA014486 and DA026430]
- Progetto Operativo Nazionale [PON01_02512]
- FIRB - MERIT [RBNE08HWLZ_006]
- GW Pharmaceutical, UK
- GW Pharmaceuticals, Allergan, USA
Ask authors/readers for more resources
Ageing is characterized by the progressive impairment of physiological functions and increased risk of developing debilitating disorders, including chronic inflammation and neurodegenerative diseases. These disorders have common molecular mechanisms that can be targeted therapeutically. In the wake of the approval of the first cannabinoid-based drug for the symptomatic treatment of multiple sclerosis, we examine how endocannabinoid (eCB) signalling controls - and is affected by - normal ageing and neuroinflammatory and neurodegenerative disorders. We propose a conceptual framework linking eCB signalling to the control of the cellular and molecular hallmarks of these processes, and categorize the key components of endocannabinoid signalling that may serve as targets for novel therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available